Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 March 2025 | Story Andre Damons | Photo Andre Damons
Dr Gerard Verhoef
Dr Gerard Verhoef, an intellectual property (IP) commercialisation specialist at Barnard Incorporated Attorneys, gave an oral presentation at the second Southern African Mountain Conference.

South Africa is neglecting and overlooking the economic potential of Aloe ferox, forfeiting millions in potential revenue from this ‘green gold’. In doing so, the country is denying farmers and communities the chance to prosper from the land’s true bounty and is also undermining its biodiversity.

While South Africa harvests a mere 200 tons of Aloe ferox annually, its global competitors, such as Mexico, churn out a staggering 400 000 tons of Aloe vera, says Dr Gerard Verhoef, an intellectual property (IP) commercialisation specialist at Barnard Incorporated Attorneys. He gave an oral presentation titled IKS, the public domain and Biotrade during a session on Mountain People's Livelihoods at the second Southern African Mountain Conference (SAMC2025).

Researchers, policy makers, and practitioners from across Southern Africa and beyond came together from 17 to 20 March at the scenic Champagne Sports Resort in the central Maluti-Drakensberg for SAMC2025 themed ‘Overcoming Boundaries and Barriers’.

The next rooibos

SAMC2025, under the patronage of UNESCO and organised by the University of the Free State (UFS) Afromontane Research Unit (ARU) – in partnership with the African Mountain Research Foundation (AMRF) and the Global Mountain Safeguard Research Programme (GLOMOS) – delved into critical issues around mountain ecosystems, communities, governance, and transboundary cooperation.

Aloe ferox could be the next rooibos, which is successfully using its geographical indications (GI) status to unlock value throughout the biotrade value chain, Dr Verhoef said. Other South African plants that are also an underutilised asset with economic potential for the country, include honeybush, baobab, umsuzwane, rose geranium, imphepho, Cape chamomile, Kalahari melon, mafura, sour plum, and African ginger.

A GI consists of the name of the place of origin. It links a product to a specific geographical area, which indicates the origin of where the product is produced, processed, or prepared.

Overlooking the potential of Aloe ferox, which has been scientifically proven to contain double the amino acids and 20 times more antioxidants than its international cousin, Aloe vera, Dr Verhoef explains, South Africa is not only undermining its biodiversity but also the economy. Aloe ferox is most popularly used for its laxative effect (aloe bitters) and as a topical application to the skin, eyes, and mucous membranes. It is also used for many traditional uses as well as cosmetic purposes.

Time to capitalise

According to him, Aloe ferox remains an underutilised asset, relegated to niche markets and small-scale production due to regulatory constraints and the unwillingness to obtain access and benefit-sharing (ABC) permits needed to navigate obstacles in South Africa as well as Namibia, Botswana, Zimbabwe, and Mozambique.

“This is not just an agricultural oversight; it is a glaring economic misstep. It is high time that South Africa capitalises on its green gold, turning the tables on international competitors and finally giving Aloe ferox the global podium it deserves. This is not just an agricultural oversight; it is a glaring economic misstep.

Aloe ferox could be a flagship in the global wellness market, much like rooibos has become for tea. But until we embrace and promote our indigenous resources with the same vigour as we do foreign ones, our ‘green gold’ will remain just out of reach, a latent promise unfulfilled. It’s high time South Africa capitalise and turn the tables on international competitors, finally giving Aloe ferox the global podium it deserves,” said Dr Verhoef.

The path forward, he explains, requires a radical shift in how we view and value our native species. It demands a coalition of dedicated scientists, legal advisers, and farmers to advocate for more accommodating regulations and stronger market support. The pharmaceutical and cosmetic industries – major users of aloe products – must also be brought into the fold to help recalibrate the scales in favour of Aloe ferox. South Africa’s rich biodiversity is a national treasure, yet our approach to leveraging this wealth remains timid and fragmented.

News Archive

Stem cell research and human cloning: legal and ethical focal points
2004-07-29

   

(Summary of the inaugural lecture of Prof Hennie Oosthuizen, from the Department of Criminal and Medical Law at the Faculty of Law of the University of the Free State.)

 

In the light of stem cell research, research on embryo’s and human cloning it will be fatal for legal advisors and researchers in South Africa to ignore the benefits that new bio-medical development, through research, contain for this country.

Legal advisors across the world have various views on stem cell research and human cloning. In the USA there is no legislation that regulates stem cell research but a number of States adopted legislation that approves stem cell research. The British Parlement gave permission for research on embryonic stem cells, but determined that it must be monitored closely and the European Union is of the opinion that it will open a door for race purification and commercial exploitation of human beings.

In South Africa the Bill on National Health makes provision for therapeutical and non therapeutical research. It also makes provision for therapeutical embryonical stem cell research on fetuses, which is not older than 14 days, as well as for therapeutical cloning under certain circumstances subject to the approval of the Minister. The Bill prohibits reproductive cloning.

Research on human embrio’s is a very controversial issue, here and in the rest of the world.

Researchers believe that the use of stem cell therapy could help to side-step the rejection of newly transplanted organs and tissue and if a bank for stem cell could be built, the shortage of organs for transplants would become something of the past. Stem cells could also be used for healing of Alzheimer’s, Parkinson’s and spinal injuries.

Sources from which stem cells are obtained could also lead to further ethical issues. Stem cells are harvested from mature human cells and embryonic stem cells. Another source to be utilised is to take egg cells from the ovaries of aborted fetuses. This will be morally unacceptable for those against abortions. Linking a financial incentive to that could become more of a controversial issue because the woman’s decision to abort could be influenced. The ideal would be to rather use human fetus tissue from spontaneous abortions or extra-uterine pregnancies than induced abortions.

The potential to obtain stem cells from the blood of the umbilical cord, bone-marrow and fetus tissue and for these cells to arrange themselves is known for quite some time. Blood from the umbilical cord contains many stem cells, which is the origin of the body’s immune and blood system. It is beneficial to bank the blood of a newborn baby’s umbilical cord. Through stem cell transplants the baby or another family member’s life could be saved from future illnesses such as anemia, leukemia and metabolic storing disabilities as well as certain generic immuno disabilities.

The possibility to withdraw stem cells from human embrio’s and to grow them is more useable because it has more treatment possibilities.

With the birth of Dolly the sheep, communities strongly expressed their concern about the possibility that a new cloning technique such as the replacement of the core of a cell will be used in human reproduction. Embryonic splitting and core replacement are two well known techniques that are associated with the cloning process.

I differentiate between reproductive cloning – to create a cloned human embryo with the aim to bring about a pregnancy of a child that is identical to another individual – and therapeutically cloning – to create a cloned human embryo for research purposes and for healing human illnesses.

Worldwide people are debating whether to proceed with therapeutical cloning. There are people for and against it. The biggest ethical objection against therapeutical cloning is the termination of the development of a potential human being.

Children born from cloning will differ from each other. Factors such as the uterus environment and the environment in which the child is growing up will play a role. Cloning create unique children that will grow up to be unique individuals, just like me and you that will develop into a person, just like you and me. If we understand this scientific fact, most arguments against human cloning will disappear.

Infertility can be treated through in vitro conception. This process does not work for everyone. For some cloning is a revolutionary treatment method because it is the only method that does not require patients to produce sperm and egg cells. The same arguments that were used against in vitro conception in the past are now being used against cloning. It is years later and in vitro cloning is generally applied and accepted by society. I am of the opinion that the same will happen with regard to human cloning.

There is an argument that cloning must be prohibited because it is unsafe. Distorted ideas in this regard were proven wrong. Are these distorted ideas justified to question the safety of cloning and the cloning process you may ask. The answer, according to me, is a definite no. Human cloning does have many advantages. That includes assistance with infertility, prevention of Down Syndrome and recovery from leukemia.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept